
Pioneering Science for Patient Choice
Advancing new oral alternatives for those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
View our Science
Pharvarisaims to develop novel, oral bradykinin B2 receptor antagonists to help address unmet needs and potentially improve the standard of care for people living with HAE.
View our Pipeline
HAE CHAPTER-3
Pivotal Phase 3 study of deucrictibant for the prophylactic treatment of HAE attacks

RAPIDe-3
Pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks
Pharvaris is a leader in bradykinin-mediated diseases, aiming to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks.
View our Science
Pharvaris is committed to improving the treatment of HAE and the quality of life for people living with bradykinin-mediated angioedema.
HAE CommunityOur legacy in HAE, our scientific expertise, and our values drive our passion as we aspire to provide choice to people living with bradykinin-mediated angioedema.
About Us